

PICO[®] Single Use Negative Pressure Wound Therapy System (sNPWT) is associated with significantly lower healthcare resource utilization (HCRU) costs, and likelihood of dehiscence following orthopaedic surgery compared to PREVENA[™] in real-world use

1. Bashyal RK, Searle R, Nherera LM, Wright A. Effects of single-use negative pressure wound therapy on healthcare use: US analysis of a large claims database. *J Wound Care*. 2025;34(8):555–562.

Overview

- Retrospective review of the US PREMIER PINC AI Healthcare Database for patients receiving either PICO sNPWT or PREVENA[™] following orthopaedic surgery between January 2017–June 2022
 - The study included and compared over 17,000 adult patients
- Study endpoints included clinical and HCRU outcomes
 - Clinical outcomes included surgical site complications (SSCs)
 - HCRU outcomes included length of stay and costs at admission and post-surgery

Methodology



PREMIER Healthcare Database



8,634 PICO sNPWT patients

8,634 PREVENA[™] patients



Orthopaedic surgery

PICO sNPWT vs PREVENA[™]



Assess the effect of two sNPWT devices on HCRU and SSCs during real-world use

Results, compared to patients receiving PREVENA[™]

63.9% significantly lower odds of dehiscence with PICO sNPWT ($p<0.05$)

- Patients who received PICO sNPWT following orthopaedic surgery showed reduced odds ($p=ns$) of developing:
 - Surgical site infection (SSI) at 30 days
 - Superficial SSI at 30 days
 - Deep SSI at 90 days
 - Seroma at 30 days



29.7% significantly lower length of stay for patients receiving PICO sNPWT ($p<0.0001$)

Significantly lower costs for patients receiving PICO sNPWT ($p<0.0001$)



-21.7% reduced costs at admission



-20.67% reduced costs 30 days post-surgery



-20.78% reduced costs 90 days post-surgery

Conclusion

In real-world use, the implementation of PICO sNPWT following orthopaedic surgery demonstrated significant reductions in the odds of developing dehiscence compared to patients receiving PREVENA[™]. Additionally, PICO sNPWT demonstrated significantly lower costs and reduced financial burden to healthcare providers following orthopaedic surgery compared to patients receiving PREVENA[™].

This material is intended for Healthcare Professional use only. Study Bashyal RK et al is funded by Smith & Nephew. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.